Figure 6: Combined levels of phospho-SRC and phospho-RPS6 predict survival of TCGA GBM patients.
From: Metabolic/Proteomic Signature Defines Two Glioblastoma Subtypes With Different Clinical Outcome
GSf- (yellow) or GSr-like (brown) phenotypes were assigned to patients based on the combined expression of either SRC and RPS6 pS235-36 (A) or SRC pY527 and RPS6 pS235-36 (B) see methods section for details. Patients fulfilling the SRC/RPS6 pS235-36 median expression cut-off criterion were 58 per group while for the SRC pY527/RPS6 pS235-36 were 53 per group out of a total 211 TCGA patients analyzed. Log-rank p values, hazard ratio (with 95% confidence interval) and relative p values for the group variable are reported inside each plot.
